The virus headline is likely to dominate the nervous stock market and as a result, we are going to witness another negative opening. SGX Nifty is down by 54 points, trading at 11,671 levels.

GMR Group announced that it has entered into a partnership with Groupe ADP for a partnership in the airport business.

Inflation is considered as one of the significant components responsible for wealth destruction. So, let’s see how different asset classes fare against inflation at different times.

The domestic stock market faced losses today as both the benchmark indices ended the trading session in red, hitting three-week lows, the lowest intraday levels recorded since February 3, 2020. S&P BSE Sensex was down by more than 392 points and closed at 39,888.96 levels, down by 0.97 per cent. Nifty too followed the trail by closing at 11,678.50, down by 1.01 per cent.

Brigade Group, a leading real estate developer in India, announced on Wednesday that it had partnered with Oakter, a home automation company, to provide smart home solutions to its future residents.

The shares of Salasar Techno Engineering were up by almost five per cent on Wednesday when the company announced that it had been awarded a contract for the construction of 132/33 KV, 2X50 MVA substation at Nathkuchi (Assam) along with the associated transmission lines from Assam Electricity Grid Corporation Limited (AEGCL).

Rossari Biotech Ltd, a specialty chemicals maker has received a regulatory approval for its Initial Public Offering (IPO).

Securities and Exchange Board of India (SEBI) issued its final observations on Rossari Biotech’s draft prospectus for the IPO on February 20, according to information on the capital market regulator’s website.

CRISIL announced about the completion of acquisition of 100 per cent stake in Greenwich Associates LLC and its six subsidiaries as well. Despite this development, the stock of the company fell by more than four per cent on Wednesday.

As per the contract, the company would make an upfront payment of Rs 6,500 crore to MSRDC, followed by a staggered payment of Rs 850 crore each in one to three years and Rs 62 crore in four years, aggregating to Rs 8,262 crore for sub-concession period of ten years and two months.

Aurobindo Pharma announced of receiving an Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from USFDA for its Hyderabad facility.